Benitec Biopharma Inc has a consensus price target of $7, established from looking at the 8 latest analyst ratings. The last 3 analyst ratings were released from JMP Securities, JMP Securities, and JMP Securities on February 15, 2024, January 24, 2024, and September 26, 2023. With an average price target of $8 between JMP Securities, JMP Securities, and JMP Securities, there's an implied 48.15% upside for Benitec Biopharma Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
02/15/2024 | BNTC | Buy Now | Benitec Biopharma | $5.40 | 85.19% | JMP Securities | Silvan Tuerkcan | $8 → $10 | Maintains | Market Outperform | Get Alert |
01/24/2024 | BNTC | Buy Now | Benitec Biopharma | $5.40 | 48.15% | JMP Securities | Silvan Tuerkcan | $6 → $8 | Maintains | Market Outperform | Get Alert |
09/26/2023 | BNTC | Buy Now | Benitec Biopharma | $5.40 | 11.11% | JMP Securities | Silvan Tuerkcan | $4 → $6 | Maintains | Market Outperform | Get Alert |
06/26/2023 | BNTC | Buy Now | Benitec Biopharma | $5.40 | -25.93% | JMP Securities | Silvan Tuerkcan | → $68 | Reiterates | Market Outperform → Market Outperform | Get Alert |
05/18/2023 | BNTC | Buy Now | Benitec Biopharma | $5.40 | -25.93% | JMP Securities | Silvan Tuerkcan | $68 → $68 | Reiterates | Market Outperform → Market Outperform | Get Alert |
10/18/2022 | BNTC | Buy Now | Benitec Biopharma | $5.40 | -25.93% | JMP Securities | Silvan Tuerkcan | → $68 | Initiates | → Market Outperform | Get Alert |
09/23/2022 | BNTC | Buy Now | Benitec Biopharma | $5.40 | -25.93% | HC Wainwright & Co. | Patrick Trucchio | $170 → $68 | Maintains | Buy | Get Alert |
02/17/2022 | BNTC | Buy Now | Benitec Biopharma | $5.40 | 85.19% | HC Wainwright & Co. | Patrick Trucchio | → $170 | Initiates | → Buy | Get Alert |
The latest price target for Benitec Biopharma (NASDAQ: BNTC) was reported by JMP Securities on February 15, 2024. The analyst firm set a price target for $10.00 expecting BNTC to rise to within 12 months (a possible 85.19% upside). 5 analyst firms have reported ratings in the last year.
The latest analyst rating for Benitec Biopharma (NASDAQ: BNTC) was provided by JMP Securities, and Benitec Biopharma maintained their market outperform rating.
There is no last upgrade for Benitec Biopharma.
There is no last downgrade for Benitec Biopharma.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Benitec Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Benitec Biopharma was filed on February 15, 2024 so you should expect the next rating to be made available sometime around February 15, 2025.
While ratings are subjective and will change, the latest Benitec Biopharma (BNTC) rating was a maintained with a price target of $8.00 to $10.00. The current price Benitec Biopharma (BNTC) is trading at is $5.40, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.